• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Protein Nanoparticles for Antigen Display in Vaccines
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hep...
Source: NIH OTT Licensing Opportunities - July 6, 2020 Category: Research Authors: ott-admin Source Type: research

Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses
There is a great need for broadly protective, “universal” influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different l ow pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intra...
Source: NIH OTT Licensing Opportunities - December 5, 2019 Category: Research Authors: ajoyprabhu3 Source Type: research

A High-Yield Perfusion-Based Transient Gene Expression Bioprocess
Currently, fed-batch processes are the most commonly used bioprocesses in transient gene expression (TGE) vaccine manufacturing. However, because fed-batch processes keep all the cells and protein product in the vessel throughout the run, some limitations are intrinsic. First, waste products like cell debris or other unwanted small molecules accumulate in the vessel with a potential to disrupt the cell growth, protein production, and the stability of the generated protein of interest. Second, necessary buffer exchange and/or cell concentration steps must be performed outside of the culturing vessel. These steps are more in...
Source: NIH OTT Licensing Opportunities - December 2, 2019 Category: Research Authors: ajoyprabhu3 Source Type: research

Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences
This technology is a set of influenza virus enrichment probes developed to increase the sensitivity of sequence-based, universal detection of all influenza viruses. This universal influenza enrichment probe set contains a unique set of 46,953 biotin-labeled, RNA probes, each 120 base-pairs long, that can be used to enrich for any influenza sequences without prior knowledge of type or subtype. This probe set can capture and enrich influenza viral sequences selectively and effectively in a variety of samples, such as clinical samples with degraded nucleotides or samples containing very low amounts of influenza virus, thus ma...
Source: NIH OTT Licensing Opportunities - November 8, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens
Antigens on the surface of virus particles are displayed in a regular, repetitive pattern which facilitates B cell activation. Presenting trimeric antigens on engineered particles that mimic the geometric patterns observed for native viral proteins can lead to an improved host antibody response.Self-assembling globular ferritin nanoparticles have previously been used to display multiple copies of a co-assembled trimeric antigen to the immune system. However, prior ferritin nanoparticle technologies only permit a random co-assembly of diverse trimeric antigens, and therefore cannot guarantee the pattern and ratio of diverse...
Source: NIH OTT Licensing Opportunities - October 17, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof
Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) have designed influenza vaccine candidates based on group 2 influenza hemagglutinin (HA) proteins. These group 2 HA proteins were engineered to remove the highly variable head region and stabilize the remaining stem region. The researchers then fused the engineered group 2 HA stabilized stem with a ferritin subunit. The resulting fusion protein can self-assemble into nanoparticles which display group 2 HA stem domain trimers on their surface.These immunogens elicit cross-reactive antibodies to group 2 influenza v...
Source: NIH OTT Licensing Opportunities - October 17, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Prefusion HPIV F Immunogens and Their Use.
Human parainfluenza virus (hPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in a myriad of diseases of the respiratory tract including croup, bronchitis, and pneumonia (Mao et al., 2012). hPIV is a leading cause of respiratory tract infection and hospitalization among children under 5, only surpassed by the respiratory syncytial virus (RSV). Currently, there are limited treatment options and no approved vaccines. Recently, studies showed that a large proportion of neutralizing antibodies preferentially recognize exposed epitopes in the p...
Source: NIH OTT Licensing Opportunities - August 31, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Novel Multivalent Nanoparticle Vaccines
Current seasonal influenza vaccines are designed to elicit immunity to circulating strains of influenza each year. The targeted strains are selected based on predictions of which strains are likely to be predominant in the human population for a given year. This prediction must be made well ahead of the influenza season to allow time for vaccine production and can be inaccurate.Scientists at NIAID ' s Vaccine Research Center are developing an alternative approach for design and production of seasonal influenza vaccines. The design includes recombinant fusion proteins that self-assemble into nanoparticles with influenza ant...
Source: NIH OTT Licensing Opportunities - May 15, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof
An effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein hemagglutinin. By targeting this highly conserved region, which is nearly identical in various strains of influenza virus, these immunogens could train the immune system to defend against a wide variety of influenza strains including pandemic strains derived from animal reser...
Source: NIH OTT Licensing Opportunities - May 15, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Protein Nanoparticles for Antigen Display in Vaccines
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hep...
Source: NIH OTT Licensing Opportunities - March 9, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Neutralizing Antibodies to Influenza HA and Their Use and Identification
The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe. Current standard of care for individuals hospitalized with uncomplicated influenza infection is administration of neuraminidase inhibitors. However, frequent use of such antiviral drugs increases the risk that the virus will develop drug resistance, especially in high-ris...
Source: NIH OTT Licensing Opportunities - October 30, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody
Noroviruses are now recognized as the major cause of non-bacterial gastroenteritis in all age groups, and efforts are underway to develop an effective vaccine. The lack of a robust cell culture system for human noroviruses has complicated vaccine development. Hence, norovirus virus like particles (VLPs) have played an important role in the understanding of virus structure, immune response, antigenic diversity, and vaccine design. The development of monoclonal antibodies (MAbs) against norovirus VLPs has allowed the identification and characterization of key antigenic sites of the virus capsid and facilitated the developmen...
Source: NIH OTT Licensing Opportunities - August 24, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.IC: NIAIDNIH Ref. No.:&n...
Source: NIH OTT Licensing Opportunities - November 22, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Pages: 1  2